|
|
Post by boca1girl on Jun 7, 2019 9:12:01 GMT -5
June 7 (Reuters) - Sanofi has poached Paul Hudson from Novartis to replace Chief Executive Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday, helping send its shares almost 5 percent higher. My comment: I’m not surprised the stock rose on the news. I wonder if this could have any affect on MNKD and Afrezza? MK may be hinting at something with his latest comment. finance.yahoo.com/news/3-drugmaker-sanofi-hires-hudson-105842230.html |
|
|
|
Post by mnkdfann on Jun 7, 2019 9:32:37 GMT -5
According to what I see on the web, Brandicourt is 63, fabulously well paid, French, lives in Paris.
Do you think MK is suggesting that he might move to Mannkind? Or else what? That new guy Hudson wants to buy / partner Mannkind?
|
|
|
|
Post by boca1girl on Jun 7, 2019 9:59:44 GMT -5
According to what I see on the web, Brandicourt is 63, fabulously well paid, French, lives in Paris. Do you think MK is suggesting that he might move to Mannkind? Or else what? That new guy Hudson wants to buy / partner Mannkind? No, Brandicourt is the one who tried to kill Afrezza. Brandicourt at MNKD, not in a million years. But now that he is out, the new management may realize what a blunder he made by ditching Afrezza. The new guy comes from Novo, the maker of Tribesa. Tribesa and Afrezza seem to be a winning combination. This maybe far fetched, but there could a synergy between, Novo, Sanofi, and Mannkind. |
|
|
|
Post by joeypotsandpans on Jun 7, 2019 10:33:26 GMT -5
According to what I see on the web, Brandicourt is 63, fabulously well paid, French, lives in Paris. Do you think MK is suggesting that he might move to Mannkind? Or else what? That new guy Hudson wants to buy / partner Mannkind? No, Brandicourt is the one who tried to kill Afrezza. Brandicourt at MNKD, not in a million years. But now that he is out, the new management may realize what a blunder he made by ditching Afrezza. The new guy comes from Novo, the maker of Tribesa. Tribesa and Afrezza seem to be a winning combination. This maybe far fetched, but there could a synergy between, Novo, Sanofi, and Mannkind.Boca, the new guy (Hudson) comes from Novartis not Novo, Novo does make Tresiba and yes it is an awesome combination with Afrezza as reported by several users of both. Among other areas, Novartis is heavily concentrated in the cancer immunology area and that may more likely be why they took him on as their (Sanofi's) diabetes division has slowed down they have looked to diversify into other arenas |
|
|
|
Post by boca1girl on Jun 7, 2019 13:13:27 GMT -5
No, Brandicourt is the one who tried to kill Afrezza. Brandicourt at MNKD, not in a million years. But now that he is out, the new management may realize what a blunder he made by ditching Afrezza. The new guy comes from Novo, the maker of Tribesa. Tribesa and Afrezza seem to be a winning combination. This maybe far fetched, but there could a synergy between, Novo, Sanofi, and Mannkind.Boca, the new guy (Hudson) comes from Novartis not Novo, Novo does make Tresiba and yes it is an awesome combination with Afrezza as reported by several users of both. Among other areas, Novartis is heavily concentrated in the cancer immunology area and that may more likely be why they took him on as their (Sanofi's) diabetes division has slowed down they have looked to diversify into other arenas Well that mistake blew my whole theory! 😎 |
|
